Adverse Effects

Biomarkers

Bladder Cancer

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Cervical Cancer

Colorectal Cancer

Endometrial Cancer

Esophageal Cancer

Gastric Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancer

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Kidney Cancer

Chronic Lymphocytic Leukemia

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Leukemia

Liver Cancer

Lung Cancer

Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Follicular Lymphoma

Hodgkin Lymphoma

Mantle Cell Lymphoma

Marginal Zone Lymphoma

Lymphoma

Melanoma

Mesothelioma

Multiple Myeloma

Neuroendocrine Tumors

Non-Small Cell Lung Cancer (NSCLC)

Oncology

Ovarian Cancer

Ovarian Cancer Clincal Consult

Pancreatic Cancer

Pediatric Cancers

Prostate Cancer

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Small Cell Lung Cancer (SCLC)

Surgery

Thoracic Malignancies 

Thyroid Cancer

News

Clinical Topics

Integrative Care

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Clinical Consult

Expert Interviews

Face Off

Medical World News

Morning Rounds

OncView

Podcasts

Readout 360

Satellite Sessions

Training Academy

Year in Review

Conferences

Publications

All Journals

Editorial Board

For Authors

Events

Frontline Forum

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Subscribe

Print Subscription

eNewsletter

Videos

Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.

Genetic Prostate Cancer Studies Are Needed to Push the Needle Forward

Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022. 

On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.

Articles

Investigators are assessing BI 764532 in extensive-stage small cell lung cancer and other neuroendocrine carcinoma as part of the phase 2 DAREON-5 study.

BI 764532 Earns FDA FTD in Large Cell Lung Neuroendocrine Carcinoma

Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.

Tisotumab Vedotin Survival Data in Cervical Cancer Are “Game-Changing”

Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®. 

She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time. 

Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at 

Six BCMA-directed, CD19-directed autologous CAR T-cell therapies are under investigation for the potential risk of T-cell malignancies. 



FDA Warns BCMA-, CD19-Directed Autologous CAR T-Cell Therapy May Lead to T-Cell Malignancies

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Twitter

Spotlight

Around the Practice 

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Journal

Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Clinical

Genitourinary Cancer

Gynecologic Cancer

Skin Cancer

1rem

Authors

Smaller early-stage tumors may lend themselves to less radical lung parenchymal sparing resections or no surgery at all.

Smaller Incisions for Smaller Cancers 

Michael J. Liptay, MD

Articles